Currently, there is no effective causal treatment for peanut allergy. A chemically modified,
aluminium hydroxide adsorbed peanut extract (HAL-MPE1) for subcutaneous administration has
been developed. Results from in vitro and in vivo preclinical studies demonstrate the
immunotherapeutic potential of HAL-MPE1. Therefore, a phase I, single-centre clinical trial
has been designed to assess the safety and tolerability of HAL-MPE1 in peanut allergic
patients.